BIOMARIN PHARMACEUTICAL INC (BMRN)
A+
Pipeline Grade
Financial Position (from SEC Filings)
$3,072.4M
Cash & Equivalents
$220.7M
Quarterly Burn Rate
$10,124M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (2 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
GALSULFASE
NAGLAZYME |
APPROVED | Achondroplasia, Advanced Breast Cancer, Albuminuria, Alpha 1-Antitrypsin Deficiency, Autism Spectrum Disorder, Autistic Disorder, Autosomal Recessive Hypophosphatemic Rickets, Batten Disease, Carcinoma, Non-Small-Cell Lung, Childhood Solid Tumors, Classical Phenylketonuria(PKU), Claudication, Intermittent, CLN2, CLN2 Disease, CLN2 Disorder, Cognitive Decline, Coronary Artery Disease, Duchenne Muscular Dystrophy, Duchenne Muscular Dystrophy (DMD), Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Endothelial Dysfunction, Generalized Arterial Calcification of Infancy 1, GTP Cyclohydrolase Deficiency, Hemophilia, Hemophilia A, Hemophilia A With Anti Factor VIII, Hemophilia A With Inhibitor, HER2/Neu Negative, Hurler-Scheie Syndrome, Hyperoxaluria, Hyperphenylalaninaemia, Hyperphenylalaninemia, Hypertension, Hypochondroplasia, Isolated Systolic Hypertension, Jansky-Bielschowsky Disease, Kidney Disease, Kidney Stone, Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2, Late-onset Pompe Disease, Late-o |
|
LARONIDASE
ALDURAZYME |
APPROVED | — |
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (1)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT05368038 | ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program | OTHER | Enrolling By Invitation | 100,000 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.